Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 27Active not recruiting 16Recruiting 11Terminated 10Withdrawn 6Not yet recruiting 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 70Cyclophosphamide 44Bortezomib 41Lenalidomide 25Melphalan 24Thalidomide 19pomalidomide 17daratumumab 14fludarabine 13carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6isatuximab 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Calcium Dobesilate 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4liposomal doxorubicin 3ixazomib 3dexamethasone acetate 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × dexamethasone 21-phosphate × Plasma cell × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡